Globe Biotech renames its Covid-19 vaccine as 'Bangavax'
Published : Thursday, 3 December, 2020 at 9:44 PM Count : 642
Globe Biotech Limited has renamed its Covid-19 vaccine as 'Bangavax' changing the name of 'Bancovid' given earlier.
Manager (Quality and Regulatory Operations) of Globe Biotech Dr Mohammad Mohiuddin said they have decided to change the name of their vaccine to 'Bangavax'. They initially named the vaccine as 'Bancovid'.
"From now, it will be called 'Bangavax' as you know we want to dedicate our innovation to the father of the nation," he added.
It is learnt that the trial of 'Bangavax' in human body will start soon.
The company says that the vaccine will not require to preserve below the freezing temperature for one month. The 'Bangavax' is being produced using the technology of Pfizer and Moderna. One shot of 'Bangavax' will provide immunity to coronavirus for more than six months.
The trial of the vaccine in animal's body has already been completed. Analysing the data, the Globe Biotech Limited is claiming that 'Bangavax' is effective and provide immunity to a certain period of time.
However, Globe Biotech Limited is yet to start trial of the vaccine in human body. The company expects that it will be able to begin trial of the Bangavax in human body soon overcoming all the limitations.
Globe Biotech Limited also expect support and cooperation of all the relevant organisations of the government.
According to the WHO's draft list of possible vaccines for the novel coronavirus, 198 different vaccines are being developed in different countries.
Of the vaccines, 156 have been going through a preclinical evaluation and 42 others in clinical evaluation. Ten of them have been undergoing Phase 3 trials which are the late-stage clinical trials and determine both the efficacy and safety of the vaccine.
Novavax, Johnson & Johnson, Moderna, Pfizer AstraZeneca, Sinovac, Sinopharm, and the Murdoch Children's Research Institute have been ahead in the race for final approval to their vaccines.